Despite recent advances in understanding the biological basis of prostate cancer, the management of the disease, especially in the phase resistant to androgen ablation, remains a significant challenge.
The long latency and high incidence of prostate carcinogenesis provides the opportunity to intervene with chemoprevention in order to prevent or eradicate prostate malignancies. In this study, we have used human hormone-resistant prostate cancer cells, DU145 and PC3, as an in vitro model to assess the efficacy of xanthohumol (XN) against cell growth, motility and invasion. We observed that treatment of prostate cancer cells with low micromolar doses of XN inhibits proliferation and modulates FAK and AKT phosphorylation leading to reduced cell migration and invasion. Oxidative stress by increased production of reactive oxygen species (ROS) was associated with these effects. TRAMP transgenic mice were used as in-vivo model of prostate adenocarcinoma. Oral gavage of XN, three times per week, beginning at 4 weeks of age, induced a decrease in the average weight of the urogenital tract (UG), delayed advanced tumor progression and inhibited the growth of poorly differentiated (PD) prostate carcinoma. The ability of XN to inhibit prostate cancer in vitro and in vivo suggests that XN may be a novel agent for the management of PCa.
Written by:
Venè R, Benelli R, Minghelli S, Astigiano S, Tosetti F, Ferrari N. Are you the author?
Molecular Oncology and Angiogenesis: IRCCS Azienda Ospedaliera Universitaria San Martino - IST - Istituto Nazionale per la Ricerca sul Cancro, Largo R. Benzi 10, 16132 Genova, Italy.
Reference: Mol Med. 2012 Aug 29. Epub ahead of print.
doi: 10.2119/molmed.2012.00174
PubMed Abstract
PMID: 22952060
UroToday.com Investigative Urology Section
